1245.33 a phase 11b, randomised, double-blind, placebo controlled, parallel group, safety and efficacy study of B1 10773 (10mg and 25mg) administered orally, once daily over 78 weeks in type 2 diabetic patients receiving once – daily treatment with basal insulin (glargine or detemir of NPH insulin only) with or without concomitant metformin and or sulfonylurea therapy and insufficient glycaemic control
Authors
Roberts, Graham Dr.Affiliation
Waterford Regional HospitalIssue Date
2010-02-08Keywords
DIABETES MELLITUS